SITC Statement on anti-IL-6/IL-6R for COVID-19
To support clinicians working at the front lines of the COVID-19 pandemic, the Society for Immunotherapy of Cancer (SITC) is advocating for the pharmaceutical industry, health authorities and institutional IRBs to continue to work creatively and collaboratively to expand access to IL-6-targeting therapies for their potential use in critically-ill patients with COVID-19.
Read More >>
SITC Advocates for Scientific Journals to Grant Open Access for COVID-19 Publications
The Society for Immunotherapy of Cancer (SITC) has issued a call for all COVID-19-related research to be made open-access across all biomedical journals, to further facilitate exchange of information during the Coronavirus pandemic.
Read More >>
COVID-19 Discussion Forums
SITC has launched two new online communities to serve as discussion forums to facilitate global communication and rapidly disseminate critical information related to COVID-19. These forums aim to spark conversations between professionals on the frontlines of this pandemic—to facilitate the sharing of observations and insights in real time during the pandemic.
You need not be a SITC member to access and post in these discussion forums; all are encouraged to participate. Simply create a free CONNECT online account when prompted.